The identification of the tissue of origin leads to improved management and prognosis of patients with cancer of unknown primary (CUP)
Advances in the development of molecular platforms have enabled the achievement of higher sensitivity and specificity in the diagnosis of CUP
DNA methylation is a valid biomarker for clinical diagnosis, which enables discrimination between different tissues of origin
An epigenetic-guided prediction of tissue of origin provides a more robust CUP diagnosis than that achieved with other molecular-based platforms
The prediction of tissue of origin can provide preliminary evidence indicating the presence of particular genetic alterations for which specific treatments exist (drug-actionable targets)
Epigenetic alterations are a common hallmark of human cancer. Single epigenetic markers are starting to be incorporated into clinical practice; however, the translational use of these biomarkers has not been validated at the 'omics' level. The identification of the tissue of origin in patients with cancer of unknown primary (CUP) is an example of how epigenomics can be incorporated in clinical settings, addressing an unmet need in the diagnostic and clinical management of these patients. Despite the great diagnostic advances made in the past decade, the use of traditional diagnostic procedures only enables the tissue of origin to be determined in ∼30% of patients with CUP. Thus, development of molecularly guided diagnostic strategies has emerged to complement traditional procedures, thereby improving the clinical management of patients with CUP. In this Review, we present the latest data on strategies using epigenetics and other molecular biomarkers to guide therapeutic decisions involving patients with CUP, and we highlight areas warranting further research to engage the medical community in this unmet need.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Forbes, S. A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945–D950 (2011).
Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011).
Boehm, J. S. & Hahn, W. C. Towards systematic functional characterization of cancer genomes. Nat. Rev. Genet. 12, 487–498 (2011).
Hanahan, D. & Weinberg, R. A. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Carmona, F. J. & Esteller, M. Epigenomics of human colon cancer. Mutat. Res. 693, 53–60 (2010).
Ushijima, T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5, 223–231 (2005).
Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286–298 (2007).
Esteller, M., Corn, P. G., Baylin, S. B. & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229 (2001).
Fernandez, A. F. et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 22, 407–419 (2012).
Moran, S. et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol. 17, 1386–1395 (2016).
Löffler, H., Neben, K. & Krämer, A. CUP-Syndrom [German]. Radiologe 54, 107–111 (2014).
Stewart, J., Tattersall, M., Woods, R. & Fox, R. Unknown primary adenocarcinoma: incidence of over investigation and natural history. Br. Med. J. 1, 1530–1533 (1979).
van de Wouw, A. J., Janssen-Heijnen, M. L. G., Coebergh, J. W. W. & Hillen, H. F. P. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984–1992. Eur. J. Cancer 38, 409–413 (2002).
Fizazi, K. et al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26, 3479–3482 (2015).
Fizazi, K., Greco, F. A., Pavlidis, N. & Pentheroudakis, G. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 22, 64–68 (2011).
Collado Martin, R., Garcia Palomo, A., de la Cruz Merino, L., Borrega Garcia, P. & Baron Duarte, F. J. Clinical guideline SEOM: cancer of unknown primary site. Clin. Transl Oncol. 16, 1091–1097 (2014).
Brewster, D. H., Lang, J., Bhatti, L. A., Thomson, C. S. & Oien, K. A. Descriptive epidemiology of cancer of unknown primary site in Scotland, 1961–2010. Cancer Epidemiol. 38, 227–234 (2014).
Ferlay, J. et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. GLOBOCAN http://globocan.iarc.fr (2013).
Parkin, D. M., Whelan, S. L., Ferlay, J., Thomas, T. & Thomas, D. B. Cancer Incidence in Five Continents. IARC Sci. Publication 143 (IARC Sci. Publications, 1997).
Varadhachary, G. R. & Raber, M. N. Cancer of unknown primary site. N. Engl. J. Med. 371, 757–765 (2014).
Riihimäki, M., Hemminki, A., Sundquist, K. & Hemminki, K. Time trends in survival from cancer of unknown primary: small steps forward. Eur. J. Cancer 49, 2403–2410 (2013).
Bevier, M., Sundquist, J. & Hemminki, K. Incidence of cancer of unknown primary in Sweden: analysis by location of metastasis. Eur. J. Cancer Prev. 21, 596–601 (2012).
Shu, X., Sundquist, K., Sundquist, J. & Hemminki, K. Time trends in incidence, causes of death, and survival of cancer of unknown primary in Sweden. Eur. J. Cancer Prev. 21, 281–288 (2012).
Brustugun, O. T. & Helland, Å. Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta Oncol. 53, 134–137 (2014).
Luke, C. et al. Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Aust. N. Z. J. Public Health 32, 383–389 (2008).
Mnatsakanyan, E., Tung, W.-C., Caine, B. & Smith-Gagen, J. Cancer of unknown primary: time trends in incidence, United States. Cancer Causes Control 25, 747–757 (2014).
Pentheroudakis, G., Golfinopoulos, V. & Pavlidis, N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur. J. Cancer 43, 2026–2036 (2007).
Pavlidis, N. & Pentheroudakis, G. Cancer of unknown primary site. Lancet 379, 1428–1435 (2012).
Hainsworth, J. D., Schnabel, C. A., Erlander, M. G., Haines, D. W. & Greco, F. A. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin. Colorectal Cancer 11, 112–118 (2012).
Hainsworth, J. D. et al. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: a randomized, phase 2 trial. Cancer 121, 1654–1661 (2015).
Hainsworth, J. D. et al. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin. Oncol. 36, 44–51 (2009).
Culine, S. et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J. Clin. Oncol. 20, 4679–4683 (2002).
van de Wouw, A. J., Jansen, R. L., Griffioen, A. W. & Hillen, H. F. Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. Anticancer Res. 24, 297–301 (2004).
Abbruzzese, J. L. et al. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J. Clin. Oncol. 12, 1272–1280 (1994).
Green, A. C. Cancer of unknown primary: does the key lie in molecular diagnostics? Cytopathology 26, 61–63 (2015).
Ariza, A. et al. Update on the diagnosis of cancer of unknown primary (CUP) origin. Clin. Transl Oncol. 13, 434–441 (2011).
Kandalaft, P. L. & Gown, A. M. Practical applications in immunohistochemistry: carcinomas of unknown primary site. Arch. Pathol. Lab. Med. 140, 508–523 (2016).
Onofre, A. S. C., Pomjanski, N., Buckstegge, B. & Böcking, A. Immunocytochemical diagnosis of hepatocellular carcinoma and identification of carcinomas of unknown primary metastatic to the liver on fine-needle aspiration cytologies. Cancer 111, 259–268 (2007).
Hashimoto, K. et al. Immunohistochemical profile for unknown primary adenocarcinoma. PLoS ONE 7, e31181 (2012).
Conner, J. R. & Hornick, J. L. Metastatic carcinoma of unknown primary. Adv. Anat. Pathol. 22, 149–167 (2015).
Rubin, B. P., Skarin, A. T., Pisick, E., Rizk, M. & Salgia, R. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur. J. Cancer Prev. 10, 77–82 (2001).
Gunia, S., Koch, S. & May, M. Is CDX2 immunostaining useful for delineating anorectal from penile/vulvar squamous cancer in the setting of squamous cell carcinoma with clinically unknown primary site presenting with histologically confirmed inguinal lymph node metastasis? J. Clin. Pathol. 66, 109–112 (2012).
Anderson, G. G. & Weiss, L. Determining tissue of origin for metastatic cancers. Appl. Immunohistochem. Mol. Morphol. 18, 3–8 (2010).
Ruiz-Ruiz, F. J., Saenz-Abad, D., Hualde-Enguita, A. M. & Morales-Rull, J. L. Positron emission tomography: useful in detecting metastatic cancer of unknown primary site. Singapore Med. J. 46, 302–303 (2005).
Karapolat, I. & Kumanlıog˘lu, K. Impact of FDG-PET/CT for the detection of unknown primary tumours in patients with cervical lymph node metastases. Mol. Imaging Radionucl. Ther. 21, 63–68 (2012).
Rades, D. et al. Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. Ann. Oncol. 12, 1605–1609 (2001).
Lee, J. R. et al. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Radiology 274, 764–771 (2015).
Gutzeit, A. et al. Unknown primary tumors: detection with dual-modality PET/CT—initial experience. Radiology 234, 227–234 (2005).
Fencl, P. et al. Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary. Eur. J. Nucl. Med. Mol. Imaging 34, 1783–1792 (2007).
Nanni, C. et al. Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur. J. Nucl. Med. Mol. Imaging 32, 589–592 (2005).
Delgado-Bolton, R. C., Fernández-Pérez, C., González-Maté, A. & Carreras, J. L. Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J. Nucl. Med. 44, 1301–1314 (2003).
Kwee, T. C. & Kwee, R. M. Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur. Radiol. 19, 731–744 (2009).
Beisenayeva, A. et al. The importance of immunohistochemical studies in the diagnosis of cancer of unknown primary origin. Georgian Med. News 249, 73–80 (2015).
Biernacka, A. et al. A case of S-100 negative melanoma: a diagnostic pitfall in the workup of a poorly differentiated metastatic tumor of unknown origin. Cytojournal 13, 21 (2016).
Tothill, R. W. et al. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res. 65, 4031–4040 (2005).
Horlings, H. M. et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J. Clin. Oncol. 26, 4435–4441 (2008).
Varadhachary, G. R. et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J. Clin. Oncol. 26, 4442–4448 (2008).
van Laar, R. K. et al. Implementation of a novel microarray-based diagnostic test for cancer of unknown primary. Int. J. Cancer 125, 1390–1397 (2009).
Handorf, C. R. et al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am. J. Surg. Pathol. 37, 1067–1075 (2013).
Yoon, H. H. et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann. Oncol. 27, 339–344 (2016).
Greco, F. A., Lennington, W. J., Spigel, D. R. & Hainsworth, J. D. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J. Natl Cancer Inst. 105, 782–790 (2013).
Varadhachary, G. R. et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin. Cancer Res. 17, 4063–4070 (2011).
Ferracin, M. et al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J. Pathol. 225, 43–53 (2011).
Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148–1159 (2008).
Heyn, H. & Esteller, M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 13, 679–692 (2012).
Rando, O. J. Daddy issues: paternal effects on phenotype. Cell 151, 702–708 (2012).
Schubeler, D. Epigenetic islands in a genetic ocean. Science 338, 756–757 (2012).
Portela, A. & Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol. 28, 1057–1068 (2010).
Vizoso, M. et al. Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nat. Med. 21, 741–750 (2015).
Sakatani, T. et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 25, 1976–1978 (2005).
Sandoval, J. et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J. Clin. Oncol. 31, 4140–4147 (2013).
Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350–1354 (2000).
Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
Veeck, J. et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28, e563–564 (2010).
Ter Brugge, P. et al. Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J. Natl Cancer Inst. 108, djw148 (2016).
Lopez-Serra, P. et al. A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Nat. Commun. 5, 3608 (2014).
Nogales, V. et al. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. Oncotarget 7, 3084–3097 (2016).
Moutinho, C. et al. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. J. Natl Cancer Inst. 106, djt322 (2014).
Roll, J. D. et al. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Exp. Mol. Pathol. 95, 276–287 (2013).
Stefansson, O. A. et al. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. Epigenetics 6, 638–649 (2011).
Alvarez, S. et al. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS ONE 5, e12197 (2010).
Wilop, S. et al. Array-based DNA methylation profiling in acute myeloid leukaemia. Br. J. Haematol. 155, 65–72 (2011).
Ibragimova, I. et al. Genome-wide promoter methylome of small renal masses. PLoS ONE 8, e77309 (2013).
Lenhard, K. et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin. Gastroenterol. Hepatol. 3, 142–149 (2005).
Sabbioni, S. et al. Multigene methylation analysis of gastrointestinal tumors: TPEF emerges as a frequent tumor-specific aberrantly methylated marker that can be detected in peripheral blood. Mol. Diagn. 7, 201–207 (2003).
Sameer, A. S. & Nissar, S. Epigenetics in diagnosis of colorectal cancer. Mol. Biol. Res. Commun. 5, 49–57 (2016).
Lee, B. Bin et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin. Cancer Res. 15, 6185–6191 (2009).
Lee, W. H., Isaacs, W. B., Bova, G. S. & Nelson, W. G. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol. Biomarkers Prev. 6, 443–450 (1997).
Goessl, C. et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 1, 5941–5945 (2000).
Peng, X. et al. Accumulated promoter methylation as a potential biomarker for esophageal cancer. Oncotarget 8, 679–691 (2017).
Su, Y., Fang, H. & Jiang, F. Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection. Clin. Epigenetics 8, 109 (2016).
Wei, J. et al. Integrated analysis of genome-wide DNA methylation and gene expression profiles identifies potential novel biomarkers of rectal cancer. Oncotarget 7, 62547–62558 (2016).
Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681–8686 (1999).
Kanai, Y., Ushijima, S., Kondo, Y., Nakanishi, Y. & Hirohashi, S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int. J. Cancer 91, 205–212 (2001).
Ogino, S. et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58, 90–96 (2009).
Abe, M. et al. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res. 1, 828–834 (2005).
Asada, K. et al. Stronger prognostic power of the CpG island methylator phenotype than methylation of individual genes in neuroblastomas. Jpn. J. Clin. Oncol. 43, 641–645 (2013).
Sandoval, J. et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 6, 692–702 (2011).
Moran, S., Arribas, C. & Esteller, M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics 8, 389–399 (2016).
Heyn, H., Méndez-González, J. & Esteller, M. Epigenetic profiling joins personalized cancer medicine. Expert Rev. Mol. Diagn. 13, 473–479 (2013).
Moran, S. et al. Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray. Epigenetics 9, 829–833 (2014).
Varadhachary, G. R., Raber, M. N., Matamoros, A. & Abbruzzese, J. L. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 9, 596–599 (2008).
Hainsworth, J. D. et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J. Clin. Oncol. 31, 217–223 (2013).
Greco, F. A. Improved diagnosis, therapy and outcomes for patients with CUP. Nat. Rev. Clin. Oncol. 14, 5–6 (2016).
Varadhachary, G. R. et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int. J. Clin. Oncol. 19, 479–484 (2014).
Pavlidis, N., Petrakis, D., Golfinopoulos, V. & Pentheroudakis, G. Long-term survivors among patients with cancer of unknown primary. Crit. Rev. Oncol. Hematol. 84, 85–92 (2012).
Tothill, R. W. et al. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. J. Pathol. 231, 413–423 (2013).
Ross, J. S. et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol. 1, 40–49 (2015).
Stella, G. M. et al. MET mutations in cancers of unknown primary origin (CUPs). Hum. Mutat. 32, 44–50 (2011).
Gatalica, Z. et al. Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases. Oncotarget 5, 12440–12447 (2014).
Varadhachary, G. Carcinoma of unknown primary site: the poster child for personalized medicine? JAMA Oncol. 1, 19–21 (2015).
Amatu, A. et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. Clin. Cancer Res. 15, 2265–2272 (2013).
Amatu, A. et al. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Ann. Oncol. 27, 1062–1067 (2016).
Palma, N. A. et al. Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary. Case Rep. Oncol. 7, 503–508 (2014).
Chung, J. H. et al. A poorly differentiated malignant neoplasm lacking lung markers harbors an EML4-ALK rearrangement and responds to crizotinib. Case Rep. Oncol. 7, 7628–7632 (2014).
Petrakis, D., Pentheroudakis, G., Voulgaris, E. & Pavlidis, N. Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature. Cancer Treat. Rev. 39, 701–708 (2013).
Martinez-Cardús, A. et al. Epigenetic homogeneity within colorectal tumors predicts shorter relapse-free and overall survival times for patients with locoregional cancer. Gastroenteroogy 151, 961–972 (2016).
Stelzer, Y., Shivalila, C. S., Soldner, F., Markoulaki, S. & Jaenisch, R. Tracing dynamic changes of DNA methylation at single-cell resolution. Cell 163, 218–229 (2015).
Kantlehner, M. et al. A high-throughput DNA methylation analysis of a single cell. Nucleic Acids Res. 39, e44 (2011).
Komine, K. et al. Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary origin. Anticancer Res. 34, 3165–3168 (2014).
Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391–400 (2005).
Seligson, D. B. et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435, 1262–1266 (2005).
Schmidl, C., Rendeiro, A. F., Sheffield, N. C. & Bock, C. ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors. Nat. Methods 12, 963–965 (2015).
Rotem, A. et al. Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state. Nat. Biotechnol. 33, 1165–1172 (2015).
Hyun, B. R., McElwee, J. L. & Soloway, P. D. Single molecule and single cell epigenomics. Methods 72, 41–50 (2015).
Buenrostro, J. D. et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523, 486–490 (2015).
Rendeiro, A. F. et al. Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. Nat. Commun. 7, 11938 (2016).
Esteller, M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67–70 (1999).
Wong, I. H. et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59, 71–73 (1999).
Kristensen, L. S. et al. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin. Epigenetics 8, 95 (2016).
Vaca-Paniagua, F. et al. Targeted deep DNA methylation analysis of circulating cell-free DNA in plasma using massively parallel semiconductor sequencing. Epigenomics 7, 353–362 (2015).
Lehmann-Werman, R. et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl Acad. Sci. USA 113, E1826–E1834 (2016).
Guo, S. et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat. Genet. 49, 635–642 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01540058 (2016).
[No authors listed.] CancerTYPE ID. CancerTYPE ID https://www.cancertypeid.com (2017).
Gracia, A. et al. Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site, from USA payors perspective. Value Health 18, A356 (2015).
Gracia, A. et al. Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site, from the spanish NHS perspective. Value Health 18, A356–A357 (2015).
Lin, F. & Liu, H. Immunohistochemistry in undifferentiated neoplasm/tumor of uncertain origin. Arch. Pathol. Lab. Med. 138, 1583–1610 (2014).
Alaggio, R., Coffin, C. M. & Vargas, S. O. Soft tissue tumors of uncertain origin. Pediatr. Dev. Pathol. 15, 267–305 (2012).
Licciardello, J. T., Spitz, M. R. & Hong, W. K. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int. J. Radiat. Oncol. Biol. Phys. 17, 467–476 (1989).
Chao, A. et al. Implication of genomic characterization in synchronous endometrial and ovarian cancers of endometrioid histology. Gynecol. Oncol. 143, 60–67 (2016).
Tothill, R. W. et al. Development and validation of a gene expression tumour classifier for cancer of unknown primary. Pathology 47, 7–12 (2015).
The authors have received funding from the AGAUR 2014SGR633 grant (to M.E.), the Cellex Foudation (to M.E.), the European Development Regional Fund 'A way to achieve Europe' (grants ERDF.CIBER 2016. CB16/12/00312, PIE13/00022 (ONCOPROFILE) and SAF2014-55000-R; to M.E.), the European Union's Horizon 2020 research and innovation programme under grant agreements No 640696 and No 727264 (to M.E.), the Health and Science Departments of the Catalan regional government (Generalitat de Catalunya), Instituto de Salud Carlos III (ISCIII), and the Ministerio de Economía y Competitividad (MINECO).
A.M-C. has received honoraria from Ferrer International. M.E. has received grant support and is named in a patent from Ferrer International. S.M. and S.B. declare no competing interests.
About this article
Cite this article
Moran, S., Martinez-Cardús, A., Boussios, S. et al. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary. Nat Rev Clin Oncol 14, 682–694 (2017). https://doi.org/10.1038/nrclinonc.2017.97
Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition
Nature Communications (2021)
Scientific Reports (2021)
Der Onkologe (2021)
BMC Cancer (2020)
British Journal of Cancer (2020)